CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies.

MLA

Zanatta, Elisabetta, et al. “CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies.” Diagnostics (Basel, Switzerland), vol. 13, no. 10, May 2023. EBSCOhost, https://doi.org/10.3390/diagnostics13101715.

APA

Zanatta, E., Martini, A., Depascale, R., Gamba, A., Tonello, M., Gatto, M., Giraudo, C., Balestro, E., Doria, A., & Iaccarino, L. (2023). CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies. Diagnostics (Basel, Switzerland), 13(10). https://doi.org/10.3390/diagnostics13101715

Chicago

Zanatta, Elisabetta, Andrea Martini, Roberto Depascale, Anna Gamba, Marta Tonello, Mariele Gatto, Chiara Giraudo, Elisabetta Balestro, Andrea Doria, and Luca Iaccarino. 2023. “CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies.” Diagnostics (Basel, Switzerland) 13 (10). doi:10.3390/diagnostics13101715.